PDC and chronic kidney disease: Unlike rhEPO, PHD inhibitors ameliorate not only EPO deficiency but also inflammation and altered iron metabolism in CKD, both of which are regulated by HIF (Koury and Haase, 2015; Portolés et al., 2021).